TTP: the evolution of clinical practice Comment

In this issue of Blood, Coppo et al(1) have documented that caplacizumab is an effective targeted immunotherapy for thrombotic thrombocytopenic purpura (TTP) that has the potential to change established clinical practice.

Automated summary

The study shows that caplacizumab is an effective targeted immunotherapy for TTP, with the potential to alter established clinical practices.